Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012

Authors: Nobumichi Tanaka, Yasushi Nakai, Makito Miyake, Satoshi Anai, Takeshi Inoue, Tomomi Fujii, Noboru Konishi, Kiyohide Fujimoto

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

To assess the trends in risk classification and primary therapy of Japanese prostate cancer patients who were diagnosed between 2004 and 2012.

Methods

A total of 7768 patients who were newly diagnosed with prostate cancer at Nara Medical University and its 23 affiliated hospitals between 2004 and 2012 were enrolled. The trends in risk classification and primary therapy in 2004–2006 (prior period), 2007–2009 (middle period), and 2010–2012 (latter period) were compared.

Results

The proportion of high-risk and worse patients significantly decreased in the latter period compared to the prior period (p < 0.001), while that of intermediate-risk patients significantly increased over the years (p < 0.001). The proportion of primary androgen deprivation therapy (PADT) was 50% in the prior period, 40% in the middle period, and 30% in the latter period, respectively. The proportions of radiation therapy and active surveillance significantly increased. The proportion of radical prostatectomy remained similar over these periods (30%). The primary therapy was significantly different between the three periods (p < 0.001).

Conclusions

High-risk patients significantly decreased in the latter period. The use of PADT also significantly decreased, while radiation therapy and active surveillance significantly increased over these periods.
Literature
1.
go back to reference Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol. 2005;12:46–61.CrossRef Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol. 2005;12:46–61.CrossRef
2.
go back to reference Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, et al. Oncological outcomes of the prostate cancer patients registered in 2004: report from the cancer registration committee of the JUA. Int J Urol. 2011;18:876–81.CrossRefPubMed Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, et al. Oncological outcomes of the prostate cancer patients registered in 2004: report from the cancer registration committee of the JUA. Int J Urol. 2011;18:876–81.CrossRefPubMed
3.
go back to reference Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncol. 2010;40:588–92.CrossRefPubMed Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncol. 2010;40:588–92.CrossRefPubMed
4.
go back to reference Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003;170:S21–7.CrossRefPubMed Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003;170:S21–7.CrossRefPubMed
5.
go back to reference Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, et al. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol. 2007;37:775–81.CrossRefPubMed Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, et al. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol. 2007;37:775–81.CrossRefPubMed
6.
go back to reference Tanaka N, Hirayama A, Yoneda T, Yoshida K, Shimada K, Konishi N, et al. Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-oncological research group (NUORG)--a comparison between 2004-2006 and 2007-2009. BMC Cancer. 2013;13:588.CrossRefPubMedPubMedCentral Tanaka N, Hirayama A, Yoneda T, Yoshida K, Shimada K, Konishi N, et al. Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-oncological research group (NUORG)--a comparison between 2004-2006 and 2007-2009. BMC Cancer. 2013;13:588.CrossRefPubMedPubMedCentral
7.
go back to reference Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the veterans affairs health care system: data from CaPSURE. J Urol. 2003;170:905–8.CrossRefPubMed Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the veterans affairs health care system: data from CaPSURE. J Urol. 2003;170:905–8.CrossRefPubMed
8.
go back to reference Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14–9.CrossRefPubMedPubMedCentral Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14–9.CrossRefPubMedPubMedCentral
9.
go back to reference Onozawa M, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, et al. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. Jpn J Clin Oncol. 2014;44:969–81.CrossRefPubMed Onozawa M, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, et al. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. Jpn J Clin Oncol. 2014;44:969–81.CrossRefPubMed
10.
go back to reference Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Grading Committee ISUP. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228–42.CrossRefPubMed Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Grading Committee ISUP. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228–42.CrossRefPubMed
11.
go back to reference Tanaka N, Asakawa I, Kondo H, Tanaka M, Fujimoto K, Hasegawa M, et al. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients. Int J Urol. 2009;16:70–4.CrossRefPubMed Tanaka N, Asakawa I, Kondo H, Tanaka M, Fujimoto K, Hasegawa M, et al. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients. Int J Urol. 2009;16:70–4.CrossRefPubMed
12.
go back to reference Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011;79:1310–7.CrossRefPubMed Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011;79:1310–7.CrossRefPubMed
13.
go back to reference Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol. 2011;185:495–500.CrossRefPubMed Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol. 2011;185:495–500.CrossRefPubMed
14.
go back to reference Tanaka N, Fujimoto K, Hirayama A, Samma S, Momose H, Kaneko Y, et al. The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration. BMC Urol. 2011;11:6.CrossRefPubMedPubMedCentral Tanaka N, Fujimoto K, Hirayama A, Samma S, Momose H, Kaneko Y, et al. The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration. BMC Urol. 2011;11:6.CrossRefPubMedPubMedCentral
Metadata
Title
Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012
Authors
Nobumichi Tanaka
Yasushi Nakai
Makito Miyake
Satoshi Anai
Takeshi Inoue
Tomomi Fujii
Noboru Konishi
Kiyohide Fujimoto
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3637-2

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine